Adaptimmune

Adaptimmune is built around a singular conviction: that engineered T-cells can be directed to fight cancer with precision and durability. The clinical-stage biopharmaceutical company focuses exclusively on cancer immunotherapy, developing cell therapies designed to arm a patient's own immune system against malignant disease.

The company's pipeline has centred on next-generation T-cell receptor (TCR) therapies. Its named programmes include TECELRA, lete-cel, afami-cel, and uza-cel, all of which have been the subject of significant corporate activity. Adaptimmune announced the sale of these four cell therapies to US WorldMeds, a transaction that marks a strategic inflection point for the organisation and underscores the commercial value of its therapeutic assets.

Trading on the Nasdaq under the ticker ADAPY, Adaptimmune has operated as a publicly listed entity, giving investors and industry partners visibility into its governance, pipeline progress and financial position. Its focus on T-cell receptor therapy places it within a specialised and competitive segment of oncology drug development, where target specificity and manufacturing scalability remain defining challenges.

As a clinical-stage business, Adaptimmune's work sits at the intersection of translational science and commercial development, with programmes advancing from research through to patient-facing trials. The company publishes its pipeline status and scientific findings openly, providing industry professionals and research partners with access to its methodology and clinical data.

Further information is available at adaptimmune.com.